about
The need for a rapid and comprehensive adoption of the revised European standard population in cancer incidence comparisons.Indicators of the standard of care for melanoma: Tuscany data.Prognostic variability among nonsmall cell lung cancer patients with pathologic N1 lymph node involvement. Epidemiological figures with strong clinical implications.Gender differences in non-small cell lung cancer: a population-based study.Cytopathological diagnosis in a cancer registry: a useful diagnostic tool?Up-to-date estimates of breast cancer survival for the years 2000-2004 in 11 European countries: the role of screening and a comparison with data from the United States.Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer typesClassic Kaposi's sarcoma in Italy, 1985-1998Incidence of thyroid cancer in Italy, 1991-2005: time trends and age-period-cohort effects.Cost profiles of colorectal cancer patients in Italy based on individual patterns of care.Using the Benford's Law as a First Step to Assess the Quality of the Cancer Registry DataBalancing harms and benefits of service mammography screening programs: a cohort study.Breast cancer survival in the US and Europe: a CONCORD high-resolution study.Risk of cancer in persons with AIDS in Italy, 1985-1998.Cancer prevalence in United States, Nordic Countries, Italy, Australia, and France: an analysis of geographic variability.Comparing cancer care, outcomes, and costs across health systems: charting the course.Initial treatment for newly diagnosed elderly colorectal cancer patients: patterns of care in Italy and the United States.Variation in 'standard care' for breast cancer across Europe: a EUROCARE-3 high resolution study.Consistency and inconsistency in testing biomarkers in breast cancer. A GRELL study in cut-off variability in the Romance language countries.Suicide mortality is decreasing among cancer patients in Central Italy.Variability of cancer risk within an area: time to complement the incidence rate.ABO blood group and risk of cutaneous malignant melanoma.Melanoma incidence in central Italy will go on increasing also in the near future: a registry-based, age-period-cohort analysis.Improvement of malignant/benign ratio in excised melanocytic lesions in the 'dermoscopy era': a retrospective study 1997-2001.Changes in cervical cancer incidence following the introduction of organized screening in Italy.Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study.Melanoma survival: sex does matter, but we do not know how.Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?How staging of thin melanoma is changed after the introduction of TNM 7th edition: a population-based analysis.RE: How many etiological subtypes of breast cancer: two, three, four, or more?Do big numbers assure high-quality of data?Colorectal cancer incidence rates have decreased in central Italy.Trends in colorectal incidence by anatomic subsite from 1985 to 2005: a population-based study.Early diagnosis, not differential treatment, explains better survival in service screening.The risk of developing a second, different, cancer among 14 560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian Network of Cancer Registries).An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence.Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening.Non-segmental vitiligo and psoriasis comorbidity - a case-control study in Italian patients.Expansion of natural killer cells in patients with head and neck cancer: detection of "noninhibitory" (activating) killer Ig-like receptors on circulating natural killer cells.Methods for second primary cancer evaluation have to be standardized.
P50
Q30489020-EA6C4C10-37A5-45A1-9A37-95CE7B59402BQ30636554-2F75CDB7-AA8B-4F05-BE0D-2735B2660135Q33259551-F8879E27-41A3-48A9-918D-A0D2B5CA9A99Q33274303-50011720-5EF9-4478-9347-3E6631019C08Q33276603-A60443FE-CC5A-4009-BFC9-7CADC3039610Q33717807-DB65960B-CA8C-42EA-B1F1-639E46C56993Q34395344-F08CAFB1-B9DD-4559-BBBA-4D6A178DB846Q34552954-274FA2F8-B04F-4485-AF02-6970BCD0B89FQ34624429-A387B0DC-3466-437E-BCE8-F1BC6B30E4CCQ34798586-CBC9C8B4-2E9E-41EB-9B39-C4288375B33EQ36176810-266CFA00-94CA-468D-9229-FFDCFB63B739Q36393116-B999F4A6-F66D-49BA-99DD-9958371F606CQ36446450-01C88C41-2280-4EEC-BB1E-5D71DDEFF98BQ36670737-A2CC3CB3-E3F8-4032-B6F9-613CA319BA77Q37003341-E83722FF-78AF-4FDF-AC8E-F24BC79E9825Q37383675-07400DE7-70AE-48C9-8A61-6223B2F9E295Q37463523-0F0AB652-8255-475A-8E8D-708C419D2F36Q38417399-44B39E48-578F-4205-BF10-0A509747BA31Q38426380-352EF641-A9B0-43BD-8CFB-36FCB509CEEEQ38479093-DE84810E-2E9F-49DC-8FB4-4EED279605F5Q38707012-30FC26A0-0F9B-4E0E-805F-8B6477DF9C4FQ39781574-EAFE7D97-1D89-4B24-A8C3-CE1A0B52C3B0Q40252036-F78F4434-9261-4442-8BA0-986F44390855Q40515967-40E04D2F-5B90-4F11-878F-14B3862A3D24Q41146852-AE34F6AB-7807-4CA1-989C-FF890A9E54C4Q41286210-643D7EE9-447B-4503-BE5D-42D5DC9307BAQ41489861-8838D1BD-216E-4F53-BD75-C78A2B4377F5Q41548112-2744733C-D61F-4998-B96D-2923FD85C94CQ41639791-F707069D-D14A-4CB7-8C59-37DC25A54B4AQ43405715-97139E99-44DA-449A-85AD-CA14D45F94A1Q44491048-E9B1A47F-CE7F-42BC-89B3-B2F5462CBE39Q44779739-808B4262-E299-4B12-A2D6-A0999CFEAC65Q44812992-908AE3BB-DACA-4136-9576-02440A43E4D1Q44824710-6A7B822E-DB16-42D1-B22F-1601CA276268Q45595175-5F2F1C3F-F0B1-4B35-80DA-D2491E10281CQ45762231-AC9BE3DD-D856-40EC-8CEC-B824AFF62622Q45847753-24D0AB97-D169-4D60-A4D1-AAB01C75B050Q45899004-738C4F56-F0BE-453B-8B81-B4B771874B05Q48012077-A46A32B1-EB04-467F-A267-9689C2EB3A32Q48310088-4105802E-3645-453C-9B5A-1104CF3B6A7A
P50
description
researcher
@en
name
E Crocetti
@en
E Crocetti
@nl
type
label
E Crocetti
@en
E Crocetti
@nl
prefLabel
E Crocetti
@en
E Crocetti
@nl
P106
P31
P496
0000-0002-4649-2034